Is treating Blood pressure alone enough to protect your

More documents

Recommendations

Info

ASCOT: Integration of antihypertensive regimens with statin ( CADUET) Primary endpoint: Nonfatal MI and fatal CHD P=0.001 Significant effects evident within the first 3 months of treatment (p=0.02) A previously unseen 53% reduction in CV events in just 3.3 years Courtesy of Appel G, 2006. Adapted from Dahlöf B et al. www.ascotstudy.org. The Collaborative Atorvastatin Diabetes Study y( (CARDS) 1 : Can atorvastatin protect patients at increased CV risk? Cumulative hazard of primary endpoint 1 CARDS: Multicentre, randomised study in Type II diabetes patients without dyslipidaemia or documented history of CVD, given atorvastatin 10mg/day (n=1428) or placebo (n=1,410). Primary endpoint was time to first occurrence of acute CHD events, coronary revascularisation or stroke. The trial was stopped 2 years earlier than planned because the pre-specified early stopping rule for efficacy had been met. Median duration of follow-up: 3.9 years. 84% of patients in both groups were hypertensive 1.Colhoun HM et al. on behalf of the CARDS investigators. Lancet 2004; 364: 685-696.
CADUET.. The Dual Efficacy in a Single Pill Gemini data show that Caduet reduces components of CV risk across a broad range of patients you see every day n=1220 14 week These results demonstrate that treatment with Caduet either alone, or in addition to existing antihypertensive agents, is an effective and safe treatment to reduce total CHD risk. Physicians were able to titrate from 5 mg/10 mg to 10 mg/80 mg. Erdine S, et al. Single-pill amlodipine / atorvastatin helps patients of diverse ethnicity attain recommended goals for blood pressure and lipids (the Gemini-AALA ,1-15.2008study). Journal of Human Hypertension. CADUET.. The Dual Efficacy in a Single Pill Caduet - significantly reduced blood pressure and LDL-C JEWEL l Study - 1138 patients with hypertension and dyslipidaemia 16 week Caduet effectively reduced systolic BP (SBP) and low-density lipoprotein cholesterol (LDL-C) levels, and enabled more patients to achieve BP and LDL-C goals. Physicians were able to titrate from 5 mg/10 mg to 10 mg/80 mg. Curran MP. Amlodipine/Atorvastatin A Review of its Use in the Treatment of Hypertension and Dyslipidaemia and the Prevention of Cardiovascular Disease. Drugs 2010; 70 (2): 191-213
Page 1 and 2: The challenge of protection in hype
Page 3 and 4: Treating a Single Risk Factor is No
Page 5 and 6: Current Guidelines Recognize the Re
Page 7 and 8: Circulating oxidized LDL and Hypert
Page 9 and 10: Treatment of Associated Risk Factor
Page 11: Want to go beyond blood pressure in
Page 15 and 16: Is it just an antihypertensive t i
Page 17 and 18: ASCOT: Integration of antihypertens
Page 19 and 20: Case Study - Female - 45 years old
Page 21 and 22: 3 0 5 2 4 0 14 Framingham: 10-Year
Page 23 and 24: 3 -3 5 0 4 0 9 ASCOT: Integration o

Is treating Blood pressure alone enough to protect your

Create successful ePaper yourself

Delete template?

Save as template?